In a report published Friday, UBS Investment Research analyst Steven Valiquette reiterated a Buy rating on Cardinal Health CAH, and raised the price target from $53.00 to $58.00.
In the report, UBS Investment Research noted, “In our view, a key takeaway from the CAH F4Q13 conf call is that mgmt remains upbeat about the company's growth prospects in the near-term despite the loss of the WAG contract. Moreover, the $3.45-3.60 EPS guidance for FY14 may prove to be conservative as it does not include the redeployment of incremental cash flow of ~$500 mil expected this year related to the WAG brand inventory wind-down.”
Cardinal Health closed on Thursday at $51.09.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in